Rockwell Medical

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in January 1995 and is headquartered in Wixom, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Rockwell Medical reports record revenue and eyes global expansion

Rockwell Medical's Q4 2022 earnings call showcased strong revenue growth, operational improvements, and strategic initiatives for future profitability. While challenges in expense optimization and debt reduction persist, the company's focus on growth through international partnerships and new product developments presents promising opportunities. Overall, Rockwell Medical is on track to achieve financial stability and sustained growth in the healthcare market.

Rockwell Medical reports record revenue and progress towards profitability

Rockwell Medical (RMTI) delivered strong Q1 2023 results with record revenue and progress towards profitability. The company's strategic initiatives, including the successful transition of the Baxter business, are driving growth. Despite challenges, Rockwell Medical's focus on cost reduction and business development positions it well for future success.

Rockwell Medical reports Q2 challenges but eyes profitability in 2024

Rockwell Medical's Q2 2023 performance reflects challenges in net sales and profitability but highlights strategic progress towards financial stability and growth.
The company's strengths lie in revenue increase, expense reduction, and the acquisition of Evoqua's business, positioning it for accelerated profitability.
While facing challenges in financial results and product development, Rockwell's focus on market expansion and optimization presents opportunities for future growth and revenue diversification.

Rockwell Medical posts record Q3 sales, eyes profitability in Q4

Rockwell Medical's Q3 performance reflects strong sales growth and strategic acquisitions.
While facing margin challenges, the company's focus on profitability and leadership enhancements bode well.
Opportunities lie in market dominance, operational improvements, and leveraging customer agreements.
Maintaining financial stability and pursuing growth avenues are key priorities for Rockwell's future success.

Rockwell Medical achieves historic profitability and projects strong sales growth

Rockwell Medical's Q4 2023 performance reflects significant milestones with profitability achieved and record net sales reported. The company's strategic focus on operational efficiency, growth projections, and margin improvements indicate a positive trajectory. While challenges persist, Rockwell is well-positioned to leverage opportunities for sustained growth and profitability.

Rockwell Medical reports record Q1 sales and profitability growth

Rockwell Medical delivered robust financial results in Q1 2024, showcasing growth in net sales, gross profit, and improved profitability metrics.
The company's strategic initiatives to enhance margins, optimize operations, and reduce debt position it well for future growth and value creation.
While facing challenges in a competitive market, Rockwell's unique market position and financial discipline provide a solid foundation for sustained success.

Rockwell Medical reports record-high sales and profitability, eyes global expansion

Rockwell Medical's Q3 2024 performance reflects strong financial health, profitability, and record-high sales, underpinned by strategic initiatives and partnerships.
The company faces challenges in customer dynamics but is well-positioned to capitalize on growth opportunities in at-home dialysis and international markets.
With a focus on quality, customer service, and sustainable profitability, Rockwell Medical is poised for continued success and market expansion.
Overall, Rockwell Medical's Q3 2024 earnings call highlights resilience, adaptability, and a positive outlook for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini in 1996 and is headquartered in Wixom, MI.

Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Rockwell Medical (RMTI) to Report a Decline in Earnings: What to Look Out for

WIXOM, Mich., Oct.  31, 2019  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today announced the appointment of John P. McLaughlin as its Chairman of the Board, effective immediately. Mr. McLaughlin, who joined the Board on September 5, 2019, succeeds Benjamin Wolin, who will remain on the Board of Directors.

Rockwell Medical, Inc. Appoints John P.

–  Encouraging progress for Triferic® portfolio – – Conference call at 8:30 am ET on Friday, October 25, 2019 –

Rockwell Medical, Inc.  Provides Business Update

WIXOM, Mich., Sept.  24, 2019  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is scheduled to present at the 2019 Cantor Global Healthcare Conference as follows: 

Rockwell Medical, Inc. to Present at 2019 Cantor Global Healthcare Conference

WIXOM, Mich., Sept.  05, 2019  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kidney disease (CKD), today announced the appointment of John P. McLaughlin to its Board of Directors.

Rockwell Medical, Inc. Appoints Industry Veteran John P.

After a tumultuous 2018, Rockwell Medical, Inc. has just launched Dialysate Triferic for the treatment of anemia in hemodialysis patients.

Possible Turnaround At Rockwell Medical

WIXOM, Mich., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is scheduled to present at two upcoming conferences as follows: 

Rockwell Medical, Inc. to Present at Upcoming September Conferences

Rockwell Medical's (RMTI) CEO Stuart Paul on Q2 2019 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -9.59%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q2 Loss, Lags Revenue Estimates

Shares of the thinly traded micro-cap biopharma Rockwell Medical Inc (NASDAQ: RMTI) were advancing solidly Tuesday before falling back into the red.

FDA Accepts Rockwell Medical's New Drug Application

The price of Rockwell Medical's latest stock offering wasn't right for investors.

Why Rockwell Medical Stock Is Tanking Today

Biohaven Pharmaceutical Hld

Calithera Biosciences

Eiger BioPharmaceuticals

Tuesday was a breakout day for a few biotech companies, and that was the case even before news broke that the U.S. and China would be meeting at the G20 meeting in Japan.

Tuesday’s Top BioPharma Movers Deviating from the Market

Rockwell Medical's (RMTI) CEO Stuart Paul on Q1 2019 Results - Earnings Call Transcript

Rockwell Medical (RMTI) delivered earnings and revenue surprises of 16.67% and -7.94%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Rockwell Medical (RMTI) Reports Q1 Loss, Lags Revenue Estimates

Currently, FDA approved powdered Triferic is billed within a bundled J-code that doesn't incentivize dialysis centers to use Triferic.

2 Events On The Horizon Could Make Rockwell Medical A Good Investment

Earnings Preview: Rockwell Medical (RMTI) Q1 Earnings Expected to Decline

Rockwell Medical's (RMTI) CEO Stuart Paul on Q4 2018 Results - Earnings Call Transcript

News for Rockwell Medical Stock (RMTI)